Search

Your search keyword '"Young, Sigrid"' showing total 29 results
Start Over Author "Young, Sigrid"
29 results on '"Young, Sigrid"'

1. Weight Loss Pharmacotherapy

Author

Jordan, Gabriela, Young, Sigrid, and Alemán, José O.

Abstract

The rising prevalence of obesity is of major concern. There are currently 5 Food and Drug Administration-approved medications for the treatment of obesity: orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide 3.0 mg, and semaglutide 2.4 mg. Surgical options such as bariatric surgery and endoscopic surgery induce more durable weight loss than pharmacotherapy or lifestyle interventions alone. However, patients often experience weight regain and weight loss plateau after surgery. The addition of multimodal or multihormonal pharmacotherapy is a promising tool to address these challenges. The optimal timing of obesity pharmacotherapy with surgical and endoscopic interventions requires further investigation.

Published
2024
Full Text
View/download PDF

8. Impact of the COVID-19 pandemic on colorectal cancer screening in New York City.

Author

Lee, Briton, Young, Sigrid, Williams, Renee, and Liang, Peter S

Subjects
*FECAL analysis, *IMMUNOCHEMISTRY, *COLONOSCOPY, *EARLY detection of cancer, *COLORECTAL cancer, *PRIMARY health care, *COMPARATIVE studies, *SAFETY-net health care providers, *DESCRIPTIVE statistics, *RESEARCH funding, *PROPRIETARY hospitals, *COVID-19 pandemic
Abstract

Background: The COVID-19 pandemic significantly impacted the delivery of cancer screening. The resulting decrease in outpatient visits and cancellations of non-urgent procedures have negatively affected colorectal cancer (CRC) screening. We aimed to determine the effect of the pandemic on CRC screening at a safety-net hospital and a private health system based in New York City. Methods: We identified individuals eligible for CRC screening aged 50 to 75 years presenting for outpatient care at a safety-net public hospital and private health system in April through September of 2019 and 2020. The primary outcome was the proportion of screening-eligible patients seen in primary care who underwent CRC screening. Results: The safety-net hospital had 516 (6.1% of screening-eligible individuals) and 269 (4.3%) screening tests completed in 2019 and 2020, respectively (p < 0.01). Fecal immunochemical tests (FIT) accounted for 69.6% of screening in 2019 and 88.1% in 2020. Colonoscopy accounted for 20.3% of screening in 2019 and 11.9% in 2020. The private health system had 39 (0.7%) and 21 (0.6%) screening tests completed in 2019 and 2020, respectively (p = 0.48). FIT accounted for 61.9% of screening in 2019 and 57.1% in 2020. Colonoscopy accounted for 38.1% of screening in 2019 and 42.9% in 2020. Conclusion: Absolute numbers of screening tests decreased for both institutions during the COVID-19 pandemic. We observed a decrease in screening uptake and increase in proportional FIT use in the safety-net hospital but no change in the private health system. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. P024 Anorectal Manometry in Patients with Fecal Incontinence After Ileal Pouch-Anal Anastomosis for Inflammatory Bowel Disease: A Cohort Study

Author

Young Sigrid, Chang Shannon, and Smukalla Scott

Subjects
medicine.medical_specialty, Hepatology, business.industry, Anorectal manometry, Gastroenterology, medicine.disease, Inflammatory bowel disease, Ileal Pouch Anal Anastomosis, Internal medicine, Medicine, Fecal incontinence, In patient, medicine.symptom, business, Cohort study
Published
2021

21. Contributors

Author

Allen-Brady, Kristina, Azpiroz, Fernando, Bali, Neetu, Bashashati, Mohammad, Bedell, Alyse, Burton Murray, Helen, Camilleri, Michael, Cangemi, David J., De Giorgio, Roberto, Desai, Meeta R., Di Lorenzo, Carlo, Diaz, Jesus R., Eichler, Evelin, Espino, Karina, Fass, Ronnie, Fukudo, Shin, Gajendran, Mahesh, Ghafoor, Adil, Gonzalez, Zorisadday, Gyawali, C. Prakash, Harris, Lucinda A., Heinrich, Henriette, Hongo, Michio, Horowitz, Michael, Jain, Anand S., Johnson, Kathleen, Jones, Karen L., Karunaratne, Tennekoon, Keefer, Laurie, Kuo, Braden, Lacy, Brian E., Lembo, Anthony, Levinthal, David J., Loganathan, Priyadarshini, Lu, Peter L., Malagelada, Carolina, Malcolm, Allison, Malik, Zubair, McCallum, Richard W., Mittal, Ravinder K., Nadpara, Neil, Nowak, Thomas, Ortega, Andrew J., Ouyang, Ann, Pandolfino, John E., Rao, Satish S.C., Rayner, Christopher K., Remes-Troche, Jose M., Rezaie, Ali, Robles, Alejandro, Saito, Akira, Sanvanson, Patrick, Schey, Ron, Scott, S. Mark, Shaker, Reza, Sharma, Amol, Smukalla, Scott, Staller, Kyle, Stanghellini, Vincenzo, Sundar, Sahaana, Tansel, Aylin, Tuteja, Ashok K., Valdovinos-Díaz, Miguel A., Wald, Arnold, Wo, John, Young, Sigrid S., and Zheng, Ting

Published
2023
Full Text
View/download PDF

23. Neuropsychiatric Associations With Gender, Illness Duration, Work Disability, and Motor Subtype in a U.S. Functional Neurological Disorders Clinic Population

Author

Matin, Nassim, primary, Young, Sigrid S., additional, Williams, Benjamin, additional, LaFrance, W. Curt, additional, King, Julie N., additional, Caplan, David, additional, Chemali, Zeina, additional, Weilburg, Jeffery B., additional, Dickerson, Bradford C., additional, and Perez, David L., additional

Published
2017
Full Text
View/download PDF

24. Cingulo-Insular Structural Alterations Associated with Psychogenic Symptoms, Childhood Abuse and PTSD in Functional Neurological Disorders (S18.008)

Author

Perez, David, primary, Matin, Nassim, additional, Barsky, Arthur, additional, Costumero-Ramos, Victor, additional, Makaretz, Sara, additional, Young, Sigrid, additional, Sepulcre, Jorge, additional, LaFrance, W. Curt, additional, Keshavan, Matcheri, additional, and Dickerson, Bradford, additional

Published
2017
Full Text
View/download PDF

25. Neuropsychiatric Associations with Gender, Illness Duration and Work Disability Status in a U.S. Based Functional Neurological Disorders Clinic Population (P6.207)

Author

Matin, Nassim, primary, Young, Sigrid, additional, Williams, Benjamin, additional, LaFrance, W. Curt, additional, King, Julie, additional, Caplan, David, additional, Chemali, Zeina, additional, Weilburg, Jeffrey, additional, Dickerson, Bradford, additional, and Perez, David, additional

Published
2017
Full Text
View/download PDF

26. Cingulo-insular structural alterations associated with psychogenic symptoms, childhood abuse and PTSD in functional neurological disorders

Author

Perez, David L, primary, Matin, Nassim, additional, Barsky, Arthur, additional, Costumero-Ramos, Victor, additional, Makaretz, Sara J, additional, Young, Sigrid S, additional, Sepulcre, Jorge, additional, LaFranceJr, W Curt, additional, Keshavan, Matcheri S, additional, and Dickerson, Bradford C, additional

Published
2017
Full Text
View/download PDF

29. Weight Loss Pharmacotherapy: Current and Future Therapies.

Author

Jordan G, Young S, and Alemán JO

Subjects
Humans, Bariatric Surgery methods, Orlistat therapeutic use, Phentermine therapeutic use, Liraglutide therapeutic use, Bupropion therapeutic use, Topiramate therapeutic use, Glucagon-Like Peptides therapeutic use, Anti-Obesity Agents therapeutic use, Weight Loss, Obesity, Naltrexone therapeutic use
Abstract

The rising prevalence of obesity is of major concern. There are currently 5 Food and Drug Administration-approved medications for the treatment of obesity: orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide 3.0 mg, and semaglutide 2.4 mg. Surgical options such as bariatric surgery and endoscopic surgery induce more durable weight loss than pharmacotherapy or lifestyle interventions alone. However, patients often experience weight regain and weight loss plateau after surgery. The addition of multimodal or multihormonal pharmacotherapy is a promising tool to address these challenges. The optimal timing of obesity pharmacotherapy with surgical and endoscopic interventions requires further investigation., Competing Interests: Disclosure J.O. Alemán is a consultant for Novo Nordisk and clinical advisory board member for Intellihealth. The authors declare that they have no relevant or material financial interests that relate to the data described in this study. Funding Doris Duke Charitable Foundation (JOA), American Heart Association 17- SFRN33490004 (JOA), NIH K08 DK117064 (JOA), NIH NHLBI P01 HL 160470-01A1 (JOA)., (Published by Elsevier Inc.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results